SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

We evaluated the use of blood serum N-glycan fingerprinting as a tool for the diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis induced by hepatitis B virus (HBV). A group of 450 HBV-infected patients with liver fibrosis or cirrhosis with or without HCC were studied. HCC was diagnosed by α-fetoprotein (AFP) analysis, ultrasonography, and/or computed tomography and was studied histologically. N-glycan profiles of serum proteins were determined with DNA sequencer–based carbohydrate analytical profiling technology. In this study, we found that a branch alpha(1,3)-fucosylated triantennary glycan was more abundant in patients with HCC than in patients with cirrhosis, patients with fibrosis, and healthy blood donors, whereas a bisecting core alpha(1,6)-fucosylated biantennary glycan was elevated in patients with cirrhosis. The concentration of these 2 glycans and the log ratio of peak 9 to peak 7 (renamed the GlycoHCCTest) were associated with the tumor stage. Moreover, for screening patients with HCC from patients with cirrhosis, the overall sensitivity and specificity of the GlycoHCCTest were very similar to those of AFP. Conclusion: This study indicates that a branch alpha(1,3)-fucosylated glycan is associated with the development of HCC. The serum N-glycan profile is a promising noninvasive method for detecting HCC in patients with cirrhosis and could be a valuable supplement to AFP in the diagnosis of HCC in HBV-infected patients with liver cirrhosis. Its use for the screening, follow-up, and management of patients with cirrhosis and HCC should be evaluated further. (HEPATOLOGY 2007.)

Hepatocellular carcinoma (HCC) is one of the most common cancers and one of the leading causes of death worldwide.1 HCC arises most commonly in cirrhotic livers following an infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).2, 3 Indeed, liver cirrhosis is an important cause of death and a major risk factor for the development of HCC, and 60%–80% of HCCs are preceded by cirrhosis.4 Therefore, screening cirrhosis populations for early-stage HCC can reduce mortality.

Various imaging techniques are used to diagnose HCC, such as ultrasonography, computed tomography scanning, and magnetic resonance imaging.5, 6 However, these techniques cannot distinguish benign hepatic lesions, such as dysplastic nodules and cirrhotic macronodules, from HCC. For a long time, serum tumor markers have been used as an effective method for detecting malignant tumors,7–9 and they could be valuable supplements to ultrasonography and computed tomography in the diagnosis of HCC.10–12 Serum α-fetoprotein (AFP) is the only serum marker that is widely used for the diagnosis and follow-up of HCC.13, 14 A recent meta-analysis has shown that the sensitivity and specificity of AFP vary widely and that these variations cannot be entirely attributed to the threshold effect of the different cutoff levels used.15 Other improved serological markers, whether used alone or together with others, are needed for the early detection of HCC.

Most serum N-linked glycoproteins are synthesized by the liver and B-lymphocytes. Any changes in the serum total N-glycans could reflect an alteration of the liver or B-lymphocyte physiology. Because the sugar chains of glycoproteins are important for maintaining the ordered social behavior of differentiated cells in multicellular organisms, alterations in the sugar chains contribute to the molecular basis of abnormalities such as the invasion of tumor cells into the surrounding tissues and their metastasis. Alterations in the N-linked sugar chains are indeed found in various tumors.6, 16–18 Until recently, the use of glycomics in diagnosis has been limited by the lack of appropriate analytical techniques, but at least in the case of the serum N-glycome, this has been overcome.19, 20

This study was aimed at evaluating the use of blood serum N-glycan fingerprinting as a tool for the diagnosis of HCC in patients with cirrhosis induced by HBV.

Patients and Methods

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Patient Selection.

The study was approved by the Ethics Committee of Peking University Health Science Centre and by the Ethics Committee of Renji Hospital of Shanghai Second Medical University. Informed consent was obtained from each patient.

Patients were recruited from 4 hospitals in Beijing, China (Youan Hospital, Wujing Hospital, Ditan Hospital, and Beida Hospital), from Nanjing 2nd Hospital in Nanjing, China, and from Shanghai Hospital in Shanghai, China. In all, 497 HBV-infected patients with chronic liver diseases were recruited; 47 were excluded because of metastasis, autoimmune liver disease, drug-related hepatitis, alcoholic hepatitis, or obstructive jaundice. All patients were negative for antibodies against hepatitis A virus, HCV, and hepatitis D virus (enzyme immunoassay; Abbott Laboratories), Epstein-Barr virus and cytomegalovirus (enzyme immunoassay; Human Co., Ltd., Germany), and hepatitis E virus (enzyme immunoassay; Genelabs, Singapore).

Laboratory Tests.

The main clinical and biological data of the patients are summarized in Table 1. All patients had either fibrosis or cirrhosis and were infected with HBV, which was diagnosed by the serological detection of hepatitis B surface antigen (HBsAg), anti–HBsAg, hepatitis B e antigen (HBeAg), anti–hepatitis B e antigen (HBeAb), anti–hepatitis B core antigen (HBcAb), and HBV DNA. The extent of liver damage was assessed by the measurement of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, albumin, total serum protein, and γ-glutamyltransferase (GGT).

Table 1. Characteristics of HBV-Infected Chinese Patients with HCC and Cirrhosis
Case GroupCirrhosis + HCCCirrhosis − HCC
Case number22780
Male number201 (88.5%)54 (67.5%)
Age (years)53.2 ± 10.450.2 ± 11.5
HBV DNA (copy)4.4 × 106 ± 1.9 × 1073.6 × 107 ± 1.0 × 108
HBsAg+ (%)87.595
HBeAg+ (%)30.541.3
HBeAb+ (%)50.842.5
HBcAb+ (%)92.295
AST (IU/L)104.5 ± 208.3100.7 ± 173.5
ALT (IU/L)74.5 ± 90.492.7 ± 159.5
GGT (IU/L)172.2 ± 189.758.1 ± 45.4
Albumin (g/L)36.8 ± 6.633.9 ± 8.2
Total bilirubin (μmol/L)44.4 ± 99.932.0 ± 36.0
Total serum protein (g/L)59.0 ± 22.444.7 ± 18.9
AFP (ng/mL)34,331.2 ± 331,192.975.9 ± 227.8
Decompensated liver cirrhosis37 (16.3%)56 (70%)

Clinical Stage and Tumor Stage.

The diagnoses of liver fibrosis and cirrhosis were made by histological examinations, imaging procedures, and several liver function tests. The fibrosis stage was determined with Scheuer's classification. Liver samples were evaluated independently by 2 experienced hepatopathologists who were unaware of the glycomic results. The patients with liver fibrosis (n = 143) had been extensively studied, and their clinical data had been published previously by Zeng et al.21 Patients with liver cirrhosis were staged according to the Child-Pugh classification. Patients with cirrhosis and HCC (n = 227) were diagnosed histologically by biopsy, autopsy, and surgical specimens and clinically by ultrasonography and/or computed tomography scanning in a regular examination, and this was combined with the measurement of AFP (cutoff of 20 ng/mL). The tumor stages were ranked according to the TNM criteria22: T1, a solitary tumor without vascular invasion; T2, a solitary tumor with vascular invasion or multiple tumors of 5 cm or less; T3, multiple tumors greater than 5 cm invading the major branches of portal or hepatic veins; and T4, tumors invading adjacent organs other than the gallbladder and perforating the visceral peritoneum. All blood samples were drawn before any treatment or operation. Blood from a reference group of 130 healthy individuals, in whom HCC was excluded by ultrasound, were obtained from the Beijing and Shanghai Red Cross centers.

Processing Blood Samples for Protein N-Glycome Analysis.

The N-glycans present on the proteins in 2 μL of serum were released, labeled, and analyzed as described previously.23, 24 Labeled N-glycans were analyzed by DNA sequencer–assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE) technology with a capillary electrophoresis–based ABI3130 sequencer. Data were analyzed with GeneMapper version 3.7 software (Applied Biosystems, Foster City, CA). We measured the heights of the peaks that were detected in all the samples to obtain a numerical description of the profiles and analyzed these data with SPSS 12.0 statistical software.

Structural Characterization.

For the structural analysis of 8-amino-1,3,6-pyrenetrisulfonic acid–labeled serum N-glycans, they were first separated by normal-phase high-performance liquid chromatography (NP-HPLC) as described.23 Appropriate amounts were then digested with exoglycosidase as described previously with the following enzymes: Streptococcus pneumonia β-1,4-galactosidase (0.4 mU/digest), Jack Bean β-N-acetylhexosaminidase (10 mU/digest), bovine kidney α-fucosidase (2 mU/digest), and almond meal α-1,3/4-fucosidase (1 μU/digest; all from Prozyme, San Leandro, CA). DSA-FACE was used to analyze the digestion products.

Statistical Analysis.

Statistical analyses were performed with SPSS for Windows software (SPSS, Chicago, IL). The results are presented as the means ± the standard deviation. All reported P values are 2-tailed, with a t test used for independent samples. Pearson coefficients of correlation [with 95% confidence intervals and their associated probability (P)] were used to evaluate the relationship between the parameters. The receiver operating characteristic curve was used as an index of accuracy; values close to 1.0 indicated high diagnostic accuracy.

Results

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Altered N-Glycan Profiles in Patients with HCC and Cirrhosis.

Using DSA-FACE, we examined the N-glycome profile from desialylated sera (Fig. 1) of Chinese patients with liver fibrosis (n = 143) and liver cirrhosis with or without HCC complications (HCC, n = 227; cirrhosis, n = 80). We also analyzed the blood from healthy donors (n = 130). We quantified each peak by normalizing its height to the sum of the heights of all peaks in the profile and then statistically compared the peaks of healthy controls, patients with fibrosis, patients with cirrhosis, and patients with HCC. The relative concentrations of 9 N-glycan structures, represented as peaks, are shown in Supplementary Fig. 1.

thumbnail image

Figure 1. The upper panel shows malto-oligosaccharides as a sugar mass reference. The number of glucose units [degree of polymerization (DP)] in these structures is indicated. A typical desialylated N-glycan profile from the total serum protein is shown in the lower panels. The structures of the N-glycan peaks are shown below the panels. Peak 1 indicates an agalacto core-α-1,6-fucosylated biantennary glycan (NGA2F), peak 2 indicates an agalacto core-α-1,6-fucosylated bisecting biantennary glycan (NGA2FB), peaks 3 and 4 indicate a single agalacto core-α-1,6-fucosylated biantennary glycan (NG1A2F), peak 5 indicates a bigalacto biantennary glycan (NA2), peak 6 indicates a bigalacto core-α-1,6-fucosylated biantennary glycan (NA2F), peak 7 indicates a bigalacto core-α-1,6-fucosylated bisecting biantennary glycan (NA2FB), peak 8 indicates a triantennary glycan (NA3), peak 9 indicates a branching α-1,3-fucosylated triantennary glycan (NA3Fb), peak 10 indicates a core-α-1,6-fucosylated triantennary glycan (NA3Fc), peak 11 indicates a tetragalacto tetra-antennary glycan (NA4), and peak 12 indicates a branching α-1,3-fucosylated tetra-antennary glycan (NA4Fb). The symbols used in the structural formulas are as follows: (▪) β-linked N-acetylglucosamine, (○) β-linked galactose, (▴) α-1,3/6-linked fucose, and (●) α/β-linked mannose.

Download figure to PowerPoint

To enable specific HCC detection on a cirrhosis background, we focused on identifying glycan structures whose abundance would not increase in patients with cirrhosis but would be elevated in patients with HCC. We found 1 peak with this pattern, that is, peak 9 (Fig. 2A). The abundance of this peak was strongly associated with HCC (P < 0.0001), and this potentially indicated a common mechanism in its up-regulation. Moreover, peak 7 was significantly lower in patients with HCC than in patients with cirrhosis (P < 0.0001; Fig. 2B). The log(peak 9/peak 7) ratio was significantly elevated in patients with HCC (P < 0.0001) in comparison with patients with cirrhosis, patients with fibrosis, and healthy controls (Fig. 2C). Ultimately, we renamed the log(peak 9/peak 7) ratio the GlycoHCCTest in parallel to the GlycoCirrhoTest nomenclature that we adopted in our previous study, in which we used the same method but defined a different set of peaks.19

thumbnail image

Figure 2. Trends in derived diagnostic variables for the detection of HCC in patients with cirrhosis. The vertical axis represents the glycan values of peak 9, peak 7, and the GlycoHCCTest. (A) The glycan value of peak 9 increased in patients with HCC, whereas (B) the glycan value of peak 7 increased in patients with cirrhosis. (C) The GlycoHCCTest was significantly higher in the HCC group than in the cirrhosis, fibrosis, and control groups. The error bars represent 95% confidence intervals for the means.

Download figure to PowerPoint

The Glycan Marker Has the Same Efficacy of HCC Diagnosis as AFP.

Although the measurement of serum AFP is important in screening for HCC, previous studies15 have indicated that it is of limited utility in detecting HCC in patients with liver cirrhosis because of frequent mild elevations of AFP levels in cirrhosis. The low specificity of AFP for HCC at low thresholds was also found in our population of patients with cirrhosis, as can be seen in Table 2, which presents data for different AFP cutoff values.

Table 2. Diagnostic Values of AFP and Glycan Markers for the Detection of HCC
 HCC (n)False positive (n)Sensitivity (%)Specificity (%)
  1. n indicates case number.

AFP cutoff of 10 ng/mL174407750
AFP cutoff of 20 ng/mL162297164
AFP cutoff of 100 ng/mL129105788
AFP cutoff of 200 ng/mL11565193
AFP cutoff of 400 ng/mL10444695
GlycoHCCTest cutoff of −0.34130105788

As determined by a receiver operating characteristic curve analysis, the GlycoHCCTest could distinguish patients with HCC from patients with cirrhosis with an accuracy of 81% ± 3% (Fig. 3). The diagnostic accuracy of the glycan marker is very similar to that of the commonly used AFP marker, which had a diagnostic accuracy of 78% ± 3% in the same patient group (Fig. 3). Moreover, the GlycoHCCTest at a cutoff value of −0.34 detected HCC with 88% specificity and 57% sensitivity, which resemble those of AFP at a cutoff of 100 ng/mL (Table 2).

thumbnail image

Figure 3. Receiver operating characteristic (ROC) curve for the prediction of clinically significant detection of HCC in the cirrhosis group with the values of the GlycoHCCTest and AFP. The area under the curve (AUC) shows that the diagnosis power of the GlycoHCCTest (0.81 ± 0.03) resembles that of AFP (0.78 ± 0.03).

Download figure to PowerPoint

Glycan Alterations Are Associated with the Tumor Stage.

To evaluate the correlation between the HCC glycomic marker and tumor stage, an HCC subgroup (n = 98) with defined tumor sizes and stages was analyzed for glycomic changes. According to the TNM criteria, the patients with HCC were classified as T1 (n = 6), T2 (n = 28), T3 (n = 59), or T4 (n = 5). Because only a few patients were classified as T1 or T4, for the purpose of statistical analysis, we combined T1 with T2 as 1 group and T3 with T4 as another group. The concentration of peak 9 was higher in the T3–T4 group than in the T1–T2 group (Fig. 4A), whereas a negative correlation of peak 7 with the tumor stage was revealed (Fig. 4B). The GlycoHCCTest was positively associated with the tumor stage (P < 0.0001; Fig. 4C).

thumbnail image

Figure 4. Relationship between the tumor stages and the glycan values, AFT, GGT, and AST/ALT ratio. Ninety-eight patients with HCC with a defined tumor stage were analyzed. The levels of peak 9, GlycoHCCTest, AFP, and GGT increased significantly in the HCC group in comparison with the cirrhosis group, whereas the level of peak 7 and the AST/ALT ratio decreased significantly. The levels of peak 9, GlycoHCCTest, AFP, and GGT showed a positive association with the tumor stages, whereas peak 7 was associated negatively. No correlation of the AST/ALT ratio with the tumor stage was found. The vertical axis represents the peak heights of (A) peak 9 and (B) peak 7, (C) the GlycoHCCTest, (D) the AFP level, (E) the GGT level, and (F) the AST/ALT ratio. The error bars represent the 95% confidence interval for the means.

Download figure to PowerPoint

The AST/ALT ratio has been considered a sensitive marker of cirrhosis progression in viral hepatitis.25 GGT has also shown good sensitivity when viral hepatitis reaches the stage of causing structural damage.26 We therefore analyzed the correlation of the tumor stage with AFP, GGT, and the AST/ALT ratio in this subset of patients with HCC. As shown in Fig. 4D,E, the levels of AFP and GGT were higher in the HCC group than in the cirrhosis group (P < 0.001 and 0.006, respectively) and they were positively associated with the tumor stage (P < 0.023 and P < 0.016, respectively). The AST/ALT ratio was significantly lower in patients with HCC than in patients with cirrhosis (P < 0.0001), and its correlation with the tumor stage was not significant (P < 0.174; Fig. 4F). A Pearson correlation showed that the level of the GlycoHCCTest had no correlation with the level of AFP (P = 0.5680) and AST/ALT ratio (0.351), but it was associated with the GGT concentration (P = 0.001). GGT is also called cholestatic liver enzyme. Because obesity, heavy drinking, a fatty liver, and certain medications or herbs that are toxic to the liver can elevate GGT levels, it cannot be excluded that the high level of the GlycoHCCTest present in patients with HCC is not associated with cholestasis.

In addition, we evaluated the HCC glycomic marker in a group of patients with chronic HBV infection (n = 143). The GlycoHCCTest value was consistently constant among the fibrosis stages in patients with fibrosis, and this indicated that it was HCC-specific (Fig. 5).

thumbnail image

Figure 5. Correlation of the GlycoHCCTest marker with liver fibrosis. GlycoHCCTest values, plotted against the fibrosis stages, were assessed with the Scheuer scoring system. There was no statistically significant correlation between the GlycoHCCTest and fibrosis stages. The upper and lower fitted lines represent the 95% confidence interval for the mean values (middle fitted line).

Download figure to PowerPoint

Structural Analysis of the Glycans Allowing HCC Diagnosis in Patients with Cirrhosis.

The N-glycan structures were verified by exoglycosidase sequencing on NP-HPLC–purified fractions. Here we give an example for peaks 9 and 9′ (Fig. 6). From the major structure in fraction A (peak 9′; Fig. 6A), 3 galactoses can be removed with a β-1,4-galactosidase. When this enzyme is combined with an N-acetylhexosaminidase, 3 extra N-actylglucosamine residues are taken off. This indicates an N-glycan with 3 unmodified, fully galactosylated branches. Moreover, this structure is fucosylated, as it is sensitive to the low-specificity alpha-fucosidase (not shown). This structure is not a substrate for the alpha-1,3/4-fucosidase, and this indicates that this fucose modification is alpha-1,6–bound to the core N-acetylglucosamine. When the structure in fraction B (peak 9; Fig. 6B) is treated with the galactosidase, only 2 residues are removed. Additional hexosaminidase digestion removes 2 other residues, and this indicates that 1 of the 3 branches is modified so that it is insensitive to the enzymatic activity. This has been confirmed by its sensitivity to the alpha-1,3/4-fucosidase, which can remove a fucose only when it is bound to a branch N-acetylglucosamine residue. When all 3 enzymes are combined, an extra galactose and an N-acetylglucosamine are removed after the fucosidase removes the hindering fucose. Overall, these experiments show that peaks 9 and 9′ are isomers, differing only in the position of a fucose residue.

thumbnail image

Figure 6. Exoglycosidase sequencing of (B) peak 9 and (A) peak 9′. The total serum N-glycans were separated with NP-HPLC, and isolated fractions were treated with single or combined exoglycosidase arrays as indicated. The peaks are numbered as in Fig. 1. fuc indicates fucose; gal, galactose; and hex, N-acetylglucosamine.

Download figure to PowerPoint

To ensure that the GlycoHCCTest quantifies peak 9 and not its isomers, we performed an α-1,3/4-fucosidase digestion on the total serum (Fig. 7). This enzyme transforms peaks 9 and 12 into peaks 8 and 11, respectively; peaks 9′ and 12′ remain unaltered.

thumbnail image

Figure 7. Exoglycosidase treatment of the total serum N-glycans. The total serum N-glycans were treated with α-1,3/4-fucosidase to show that peaks 9 and 12 are those quantified in the GlycoHCCTest. This enzyme converts these structures into peaks 8 and 11, respectively, whereas their isomeric structures, 9′ and 12′, remain unchanged. The peaks are numbered as in Fig. 1.

Download figure to PowerPoint

Discussion

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Our group has developed a glycomic technology, DSA-FACE, for measuring N-glycan changes in biological fluids such as serum. We previously used this technology to assist in the diagnosis of liver cirrhosis in its compensated stage in patients with chronic HCV.19 In this study, we used this technology to analyze N-linked glycan profiles in order to identify the specific N-glycan changes that occur during the development of HCC in patients with cirrhosis infected with HBV.

We found that a branch alpha(1,3)-fucosylated triantennary glycan (NA3Fb; peak 9) was more abundant on serum glycoproteins in patients with HCC than in patients with cirrhosis and in patients with fibrosis. Previous reports have indicated that serum alpha-1-acid glycoprotein, an acute-phase protein secreted by the liver and carrying highly branched alpha(1,3)-fucosylated N-linked sugar chains, is a marker of carcinoma progression and prognosis.27 There is evidence that the serum alpha(1,3)-fucosyltransferase activity (measured with a synthetic substrate as an acceptor) is increased in patients with stomach, gastric, or ovarian cancer.28–30 The gene transfer of alpha-1,3-fucosyltransferase increases tumor growth of the PC-3 human prostate cancer cell line by enhancing adhesion to prostatic stromal cells.31 The expression of human alpha(1,3)-fucosyltransferase antisense equences inhibits selectin-mediated adhesion and liver metastasis of colon carcinoma cells.32 These results suggest that alpha(1,3)-fucosyltransferase is increased in cancer cells by a mechanism that involves sialyl Lewis X [NeuNAcα2[RIGHTWARDS ARROW]3Galβ1[RIGHTWARDS ARROW]4(Fucα1[RIGHTWARDS ARROW]3)GlcNAc[RIGHTWARDS ARROW]R; Fig. 8].

thumbnail image

Figure 8. Scheme of the reactions catalyzed by glycantransferases. The increased concentration of NA3Fb (peak 9) and the decreased level of NA2FB (peak 7) in patients with cirrhosis and HCC can be explained by the increased activity of GnT-V competing for the substrate with GnT-III and resulting in β1-6 branching of N-glycan. This, in turn, leads to enhanced expression of alpha(1,3)-fucosyltransferase, which produces Lewis X glycan. The consequences of increased expression of GlcNAcT-III are also shown. The dashed box shows an example of a Lewis structure.

Download figure to PowerPoint

Moreover, the concentration of NA3Fb (peak 9) increases with the tumor stage, whereas the level of bisecting β-linked N-acetylglucosamine [GlcNAc; bisecting core alpha(1,6)-fucosylated biantennary glycan (NA2FB), peak 7] decreases with the tumor stage. This could be due to changes in the hepatocyte glycosylation machinery concomitant with malignant transformation. Elevations of N-acetylglucosaminyltransferase III (GnT-III), which is responsible for the bisecting GlcNAc structure (NA2FB, peak 7), and N-acetylglucosaminyltransferase IV and N-acetylglucosaminyltransferase V (GnT-V), which produce multiantennary glycans (such as NA3Fb, peak 9), have been reported in human patients with cirrhosis and HCC.33–36 Although we cannot exclude a role for N-acetylglucosaminyltransferase IV at the moment, GnT-V is a well-known pro-oncogenic glycosyltransferase, and its expression is strongly up-regulated in HCCs. Several studies have shown in several cancers that GnT-III counteracts cancer progression, whereas GnT-V promotes it.37–39 The expression of GnT-V, which generates triantennary glycan (peak 9), competes for substrate (peak 6) with GnT-III, which produces bisecting GlcNAc (peak 7). This leads to an increased abundance of peak 9 and decreased abundance of peak 7 during tumor development in patients with cirrhosis and HCC (Fig. 8).

On the basis of this reasoning, we defined the GlycoHCCTest as the ratio of the triantennary branch fucosylated glycan (NA3Fb, peak 9) to the bisecting GlcNAc glycan (NA2FB, peak 7). In our group of patients with HBV cirrhosis, this GlycoHCCTest had a diagnostic accuracy of 81%, which is the same as that of AFP (78%). As it is notoriously difficult to diagnose HCC in patients with cirrhosis by the use of ultrasound imaging, the serum glycan marker could be a valuable supplement to AFP in the diagnosis of HCC in HBV-infected patients with liver cirrhosis.

Serum N-glycan profiling is a promising noninvasive method for detecting HCC in patients with cirrhosis. However, the individual variation in the blood serum profiles is still rather high. Therefore, more extensive N-glycan profiling studies on individuals should be carried out, including longitudinal samplings over long periods. Full characterization of the diagnostic efficiency of the GlycoHCCTest and its combination with AFP should be undertaken in an independent study in a distinct patient population.

In summary, hepatocytes continue to secrete serum proteins during liver disease, and the modifications or aberrations in glycosyltransferase expression patterns are reflected in the serum protein N-glycome. This study could give further insights into the molecular and cellular biology of HCC associated with the process of chronic injury. An analysis of the serum N-glycome is an innovative approach to screening patients with HCC from patients with liver cirrhosis. The usefulness of glycome diagnostics for the screening, follow-up, and management of patients with cirrhosis and HCC should be evaluated further.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

We thank Dr. Amin Bredan for editing the manuscript. We acknowledge Dr. H. Van Vlierberghe for a critical reading of the manuscript and discussions and Dr. P. De Bleser for a statistical analysis and discussion.

References

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information
  • 1
    Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215219.
  • 2
    Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005; 25(Suppl 1): 4047.
  • 3
    Koike K. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies. Clin Gastroenterol Hepatol 2005; 3(10 Suppl 2 ): S132S135.
  • 4
    Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271285.
  • 5
    Caturelli E, Bartolucci F, Biasini E, Vigliotti ML, Andriulli A, Siena DA, et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002; 97: 397405.
    Direct Link:
  • 6
    Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003; 39: 10761084.
  • 7
    Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005; 19: 9199.
  • 8
    Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 11751181.
  • 9
    El-Houseini ME, Mohammed MS, Elshemey WM, Hussein TD, Desouky OS, Elsayed AA. Enhanced detection of hepatocellular carcinoma. Cancer Control 2005; 12: 248253.
  • 10
    Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004; 130: 497513.
  • 11
    Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol 2002; 35(5 Suppl 2 ): S86S91.
  • 12
    El-Aneed A, Banoub J. Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients. Anticancer Res 2006; 26: 32933300.
  • 13
    Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1 ): S108S112.
  • 14
    Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. HEPATOLOGY 2006; 44: 15181527.
  • 15
    Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101: 513523.
    Direct Link:
  • 16
    Kobata A, Amano J. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol 2005; 83: 429439.
    Direct Link:
  • 17
    Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1999; 1473: 2134.
  • 18
    Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer 2006; 94: 287292.
  • 19
    Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004; 10: 429434.
  • 20
    Morelle W, Flahaut C, Michalski JC, Louvet A, Mathurin P, Klein A. Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. Glycobiology 2006; 16: 281293.
  • 21
    Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, Wan MB, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. HEPATOLOGY 2005; 42: 14371445.
  • 22
    Afdhal NH. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem 2004; 50: 12991300.
  • 23
    Laroy W, Contreras R, Callewaert N. Glycome mapping on DNA sequencing equipment. Nat Protoc 2006; 1: 397405.
  • 24
    Desmyter L, Fan YD, Praet M, Jaworski T, Vervecken W, De Hemptinne B, et al. Rating of CCl4-induced rat liver fibrosis by blood serum glycomics. J Gastroenterol Hepatol 2006;doi://10.1111/j.1440-1746.2006.04553.x. Available at: http://www.blackwell-synergy.com.
  • 25
    Giannini E, Risso D, Testa R. Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. Am J Gastroenterol 2001; 96: 918919.
    Direct Link:
  • 26
    Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2004; 19: 314318.
  • 27
    Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, Saniabadi AR, et al. Alpha1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 2004; 101: 28252836.
  • 28
    Yazawa S, Madiyalakan R, Izawa H, Asao T, Furukawa K, Matta KL. Cancer-associated elevation of alpha(1[RIGHTWARDS ARROW]3)-L-fucosyltransferase activity in human serum. Cancer 1988; 62: 516520.
  • 29
    Yazawa S, Asao T, Nagamachi Y, Abbas SA, Matta KL. Tumor-related elevation of serum (alpha 1[RIGHTWARDS ARROW]3)-L-fucosyltransferase activity in gastric cancer. J Cancer Res Clin Oncol 1989; 115: 451455.
  • 30
    Chandrasekaran EV, Jain RK, Matta KL. Ovarian cancer alpha 1,3-L-fucosyltransferase. Differentiation of distinct catalytic species with the unique substrate, 3′-sulfo-N-acetyllactosamine in conjunction with other synthetic acceptors. J Biol Chem 1992; 267: 2380623814.
  • 31
    Inaba Y, Ohyama C, Kato T, Satoh M, Saito H, Hagisawa S, et al. Gene transfer of alpha1,3-fucosyltransferase increases tumor growth of the PC-3 human prostate cancer cell line through enhanced adhesion to prostatic stromal cells. Int J Cancer 2003; 107: 949957.
  • 32
    Weston BW, Hiller KM, Mayben JP, Manousos GA, Bendt KM, Liu R, et al. Expression of human alpha(1,3)fucosyltransferase antisense sequences inhibits selectin-mediated adhesion and liver metastasis of colon carcinoma cells. Cancer Res 1999; 59: 21272135.
  • 33
    Mori S, Aoyagi Y, Yanagi M, Suzuki Y, Asakura H. Serum N-acetylglucosaminyltransferase III activities in hepatocellular carcinoma. J Gastroenterol Hepatol 1998; 13: 610619.
  • 34
    Song EY, Kim KS, Kim KA, Kim YD, Kwon DH, Byun SM, et al. Determination of UDP-N-acetylglucosamine: beta-D-mannoside-1,4-N-acetylglucosaminyltransferase-III in patients sera with chronic hepatitis and liver cirrhosis using a monoclonal antibody. Glycoconj J 2002; 19: 415421.
  • 35
    Yao M, Zhou DP, Jiang SM, Wang QH, Zhou XD, Tang ZY, et al. Elevated activity of N-acetylglucosaminyltransferase V in human hepatocellular carcinoma. J Cancer Res Clin Oncol 1998; 124: 2730.
  • 36
    Ito Y, Miyoshi E, Sakon M, Takeda T, Noda K, Tsujimoto M, et al. Elevated expression of UDP-N-acetylglucosamine: alphamannoside beta1,6 N-acetylglucosaminyltransferase is an early event in hepatocarcinogenesis. Int J Cancer 2001; 91: 631637.
  • 37
    Koenderman AH, Koppen PL, Koeleman CA, van den Eijnden DH. N-acetylglucosaminyltransferase III, IV and V activities in Novikoff ascites tumour cells, mouse lymphoma cells and hen oviduct. Application of a sensitive and specific assay by use of high-performance liquid chromatography. Eur J Biochem 1989; 181: 651655.
  • 38
    Koenderman AH, Wijermans PW, van den Eijnden DH. Changes in the expression of N-acetylglucosaminyltransferase III, IV, V associated with the differentiation of HL-60 cells. FEBS Lett 1987; 222: 4246.
  • 39
    Shim JK, Lee YC, Chung TH, Kim CH. Elevated expression of bisecting N-acetylglucosaminyltransferase-III gene in a human fetal hepatocyte cell line by hepatitis B virus. J Gastroenterol Hepatol 2004; 19: 13741387.

Supporting Information

  1. Top of page
  2. Abstract
  3. Patients and Methods
  4. Results
  5. Discussion
  6. Acknowledgements
  7. References
  8. Supporting Information

Supplementary material for this article can be found on the H EPATOLOGY Web site ( http://interscience.wiley.com/jpages/0270-9139/suppmat/index.html ).

FilenameFormatSizeDescription
jws-hep.21855.pdf123KSupporting Information file jws-hep.21855.pdf

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.